Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0835 or +27 21 938 0967
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202608748555077 Date of Registration: 31/08/2026
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Oral nanoviRicide (NV-387) Adaptive CLinical Evaluation for Safety and Efficacy in Ebola Virus Disease
Official scientific title An adaptive, multi-centre Phase IIA/IIB clinical trial of NV-387 oral gummies plus optimised supportive care in adults with Ebola virus disease (Bundibugyo or other orthoebolaviruses): a single-arm safety and dose run-in (Phase IIA) followed by a randomised, controlled, open-label efficacy evaluation with independent blinded-endpoint adjudication (Phase IIB)
Brief summary describing the background and objectives of the trial Ebola virus disease, caused by orthoebolaviruses, progresses over one to two weeks from “dry” and “wet” phases to multi-organ involvement or recovery. This outbreak is attributed to a divergent BDBV strain. No therapeutic or vaccine is approved specifically for BDBV; existing options have limited or unproven cross-reactivity and require intravenous infusion. An oral, broad-spectrum agent would address this gap. NV-387 is a polymeric antiviral (“nanoviricide”) designed to mimic sulfated proteoglycan structures used by enveloped viruses for cell attachment. Its proposed mechanism is decoy binding to and destabilisation of virions. It is formulated as an oral gummy. In healthy adults, single doses up to 4,000 mg and repeat doses up to 40 mg/kg were well tolerated, with no related serious adverse events. Activity has been reported against several enveloped viruses in animal models, but no filovirus-specific efficacy data exist. This trial will test BDBV activity using conservative dosing, stopping rules, continuous monitoring, and independent DSMB review. The benefit–risk balance is judged acceptable.
Type of trial RCT
Acronym (If the trial has an acronym then please provide) ORACLE BDBV
Disease(s) or condition(s) being studied Infections and Infestations
Sub-Disease(s) or condition(s) being studied Ebola
Purpose of the trial Treatment: Drugs
Anticipated trial start date 24/08/2026
Actual trial start date
Anticipated date of last follow up 31/12/2026
Actual Last follow-up date
Anticipated target sample size (number of participants) 60
Actual target sample size (number of participants)
Recruitment status Not yet recruiting
Publication URL
Secondary Ids Issuing authority/Trial register
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Randomised Simple randomization using a randomization table created by a computer software program Central randomisation by phone/fax Open-label(Masking Not Used)
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group NV387 plus Optimised supportive care Regimen by current disease stage Dry : 1,500 mg, Every 12 ± 2 h (twice daily) Wet / Critical* : 1,500 mg, Every 8 ± 2 h (three times daily) Time to sustained clinical resolution within 28 days. Phase IIA is a single-arm safety and dose run-in in which all participants receive NV-387 added to optimised supportive care (20 participants). Phase IIB is a randomised, controlled, open-label efficacy evaluation comparing NV-387 + oSOC (20 participants) against optimised supportive care alone (20 participants). The proposed regimen delivers approximately 40 mg/kg/day (twice daily) to approximately 90 mg/kg/day (three times daily) for a participant of 50 to 75 kg. First-in-human dosing established single doses up to 4,000 mg and repeat dosing up to 40 mg/kg as well tolerated; nonclinical oral no-observed-adverse-effect level (approximately 4,500 mg/kg) and maximum-tolerated-dose (approximately 7,200 mg/kg) data provide wide margins. The principal extrapolations are the multi-day treatment duration and the use in acutely ill rather than healthy individuals; these are the reasons for the dose-limiting-toxicity definitions, dose-modification rules and study-level stopping rules below and for continuous independent monitoring. 40
Control Group oSOC 28 Optimised supportive care alone 20 Active-Treatment of Control Group
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
Age ≥ 18 years. Hospitalised with clinical features compatible with BDBV (suspected case per WHO/national case definition), with the intent to confirm infection by qRT-PCR. Able to take oral or buccal medication, or expected to be able to do so during the dosing window. Written informed consent provided by the participant or, where capacity is impaired, by a legally authorised representative. Known hypersensitivity to NV-387 or to any excipient. Pregnancy or breastfeeding. Receipt of another investigational antiviral or antibody for BDBV within the prior 7 days, unless co-administration has been approved by the DSMB. A moribund state in which death is anticipated within 24 hours, such that study procedures would not be in the participant’s interest (documented clinical judgement). Any condition that, in the investigator’s judgement against pre-specified safety criteria, contraindicates participation. 80 and over: 80+ Year,Adult: 18 Year(s)-44 Year(s),Aged: 65 Year(s)-79 Year(s),Middle Aged: 45 Year(s)-64 Year(s) 18 Year(s) 100 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 04/07/2026 Institutional Health Ethics Committee at Catholic University of Bukavu
Ethics Committee Address
Street address City Postal code Country
02, Avenue de la Mission, Bugabo, Kadutu Bukavu 000000 Zaire
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome Time from first dose to sustained clinical resolution day-28 post-intervention
Secondary Outcome 28-day all-cause mortality day-28 post-intervention
Secondary Outcome Time to first negative blood qRT-PCR day-28 post-intervention
Secondary Outcome change in viral load from baseline day-3, day-5, day-7 post-intervention
Secondary Outcome Time to resolution of individual signs and symptoms day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Secondary Outcome progression to critical stage day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Secondary Outcome need for advanced care day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Secondary Outcome In-hospital all-cause mortality prior to discharge Discharge in post-intervention
Secondary Outcome time from randomisation to hospital discharge Discharge in post-intervention
Primary Outcome Incidence and severity of adverse events and serious adverse events day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Primary Outcome Events leading to treatment discontinuation day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Primary Outcome clinically significant laboratory abnormalities day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Primary Outcome events of special interest (hypersensitivity; hepatic, renal and cardiac signals). day-3, day-5, day-7, day-13, day-21, day-28, day-56 post-intervention
Secondary Outcome Health status day-56 post-intevention
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Hopital General de Reference de Rwampara Bunia Bunia Zaire
FUNDING SOURCES
Name of source Street address City Postal code Country
NanoViricides 1 Controls Drive Shelton 06484 United States of America
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Secondary Sponsor Om Sai Clinical Research Pvt Ltd C.S.T. No. 379/1-6, Karnal Chowki, Peth Bhag Sangli India Private Clinical Research Institution
COLLABORATORS
Name Street address City Postal code Country
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator Patrick de Marie Chimusa Katoto katoto.chimusa@ucbukavu.ac.cd +27799193178 02, Avenue de la Mission, Bugabo, Kadutu
City Postal code Country Position/Affiliation
Bukavu Zaire Profession Catholic University of Bukavu
Role Name Email Phone Street address
Scientific Enquiries Arsene Daniel Nyalundja arsene.nyalundja@ucbukavu.ac.cd +243994471903 106, Nyofu Avenue, Ibanda
City Postal code Country Position/Affiliation
Bukavu Zaire Chief Scientist Catholic University of Bukavu
Role Name Email Phone Street address
Public Enquiries David Mwenebintu Lupande lupande.mwenebitu@ucbukavu.ac.cd +243820462945 Avenue du Gouverneur
City Postal code Country Position/Affiliation
Bukavu Zaire Professor Catholic University of Bukavu
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes De-identified individual participant data underlying the reported results of the ORACLE-BDBV trial will be made available to qualified researchers following approval of a scientifically sound request. Direct identifiers and variables that present an unacceptable risk of participant re-identification will not be shared. Data sharing will be consistent with the informed consent document, applicable ethical, legal, and regulatory requirements, and relevant institutional and sponsor policies. Informed Consent Form,Study Protocol After the analysis and the publication of the data Will be defined later by investigator and the sponsor.
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Primary Outcome, Time from first dose to sustained clinical resolution, day-28 Primary Outcome, Time from first dose to sustained clinical resolution, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, 28-day all-cause mortality , day-28 Secondary Outcome, 28-day all-cause mortality , day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, Time to first negative blood qRT-PCR , day-28 Secondary Outcome, Time to first negative blood qRT-PCR , day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, change in viral load from baseline, day-3, day-5, day-7 Secondary Outcome, change in viral load from baseline, day-3, day-5, day-7 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, Time to resolution of individual signs and symptoms, day-3, day-5, day-7, day-13, day-21, day-28 Secondary Outcome, Time to resolution of individual signs and symptoms, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, progression to critical stage, day-3, day-5, day-7, day-13, day-21, day-28 Secondary Outcome, progression to critical stage, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, need for advanced care, day-3, day-5, day-7, day-13, day-21, day-28 Secondary Outcome, need for advanced care, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, In-hospital all-cause mortality prior to discharge, Discharge Secondary Outcome, In-hospital all-cause mortality prior to discharge, Discharge in post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, time from randomisation to hospital discharge, Discharge Secondary Outcome, time from randomisation to hospital discharge, Discharge in post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Primary Outcome, Incidence and severity of adverse events and serious adverse events , day-3, day-5, day-7, day-13, day-21, day-28 Primary Outcome, Incidence and severity of adverse events and serious adverse events , day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Primary Outcome, Events leading to treatment discontinuation, day-3, day-5, day-7, day-13, day-21, day-28 Primary Outcome, Events leading to treatment discontinuation, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Primary Outcome, clinically significant laboratory abnormalities, day-3, day-5, day-7, day-13, day-21, day-28 Primary Outcome, clinically significant laboratory abnormalities, day-3, day-5, day-7, day-13, day-21, day-28 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Primary Outcome, events of special interest (hypersensitivity; hepatic, renal and cardiac signals)., day-3, day-5, day-7, day-13, day-21, day-28, day-56 Primary Outcome, events of special interest (hypersensitivity; hepatic, renal and cardiac signals)., day-3, day-5, day-7, day-13, day-21, day-28, day-56 post-intervention
Section Name Field Name Date Reason Old Value Updated Value
Outcome OutCome List 24/08/2026 Clarification when the outcome will be assessed Secondary Outcome, Health status, day-56 Secondary Outcome, Health status, day-56 post-intevention
Section Name Field Name Date Reason Old Value Updated Value
Reporting IPD description 24/08/2026 Updated in response to the ClinicalTrials.gov review comment to include the required IPD sharing statement and clarify that de-identified participant-level data may be shared with qualified researchers under controlled-access conditions. No De-identified individual participant data underlying the reported results of the ORACLE-BDBV trial will be made available to qualified researchers following approval of a scientifically sound request. Direct identifiers and variables that present an unacceptable risk of participant re-identification will not be shared. Data sharing will be consistent with the informed consent document, applicable ethical, legal, and regulatory requirements, and relevant institutional and sponsor policies.
Section Name Field Name Date Reason Old Value Updated Value
Reporting IPD-Sharing time frame 24/08/2026 Updated in response to the reviewer comments for time frame of IPD-sharing Not applicable After the analysis and the publication of the data
Section Name Field Name Date Reason Old Value Updated Value
Reporting Key access criteria 24/08/2026 Updated in response to the reviewer comments for key access criteria. Not applicable Will be defined later by investigator and the sponsor.